Motor protein regulation of T cell receptor signaling

T 细胞受体信号传导的运动蛋白调节

基本信息

  • 批准号:
    8099462
  • 负责人:
  • 金额:
    $ 40.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-10 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The engagement of the T cell receptor (TCR) on T lymphocytes initiates signaling pathways that regulate cell proliferation, activation, and survival through the activation of transcription factors that regulate programs of gene expression. TCR signaling is initiated when an antigen presenting cell (APC) presents antigen, in the appropriate molecular context, to a T cell. After APC:T cell conjugation, the immunological synapse forms in the region of cell:cell contact. Signaling from the synapse to transcription factors requires the recruitment of signaling intermediates to the immunological synapse in a process that is incompletely understood. CARD11 is a multi-domain adapter protein that coordinates the signal-induced association of a set of proteins that are required for TCR-mediated activation of NF-kappaB. In order to expand our understanding of how CARD11 relays signals from the TCR to NF-kappaB, we have developed a novel expression cloning strategy for the identification of modulators of CARD11 signaling activity. Using this strategy, we isolated the kinesin-like motor protein GAKIN as a negative regulator of CARD11. In our preliminary studies, we have determined that GAKIN overexpression inhibits CARD11 activity and TCR signaling while the reduction in GAKIN expression results in enhanced CARD11 and TCR signaling. GAKIN and CARD11 associate at endogenous levels in T cells in a signal-inducible manner. Imaging studies suggest that the cellular localization of GAKIN changes during TCR signaling, which may depend on GAKIN's ability as a motor protein to move cargo along microtubules. In this application, we propose to test our overall hypothesis that GAKIN is a critical negative regulator of TCR signaling that regulates the scaffolding function and cellular localization of CARD11. Using biochemical approaches, we will investigate which domains of GAKIN are required for its association with CARD11 and for its ability to negatively regulate TCR signaling. We will also determine whether GAKIN modulates the association of signaling cofactors with CARD11. In imaging experiments, we will characterize how the localization of GAKIN is determined and whether GAKIN regulates the recruitment of CARD11 and signaling factors to the immunological synapse. GAKIN associates with CARD11 in a region in which oncogenic mutations have been found in Diffuse Large B cell Lymphoma (DLBCL). We will investigate whether these mutations affect GAKIN-mediated regulation of CARD11 activity and determine whether GAKIN can inhibit the dysregulated growth in DLBCL. Our results should add to the understanding of how the molecular machinery of immune cells can recognize and interpret environmental cues, including pathogenic and nonpathogenic stimuli, and respond appropriately. Since this machinery is impaired in aged T cells, dysregulated in immunodeficiencies, and is abnormally hyperactive in autoimmune disease and in several types of cancer, our results may illuminate molecular targets for the development of new therapies designed to treat multiple diseases of the immune system. PUBLIC HEALTH RELEVANCE: The normal function of the immune system depends on the ability of white blood cells, or lymphocytes, to detect foreign pathogens and respond appropriately so that a pathogen is eliminated without damage to the host. This proposal is designed to expand understanding of the molecular machinery that is used by T lymphocytes in this process. Since this machinery is impaired in aged T cells, dysregulated in immunodeficiencies, and is abnormally hyperactive in autoimmune disease and in several types of cancer, our results may illuminate molecular targets for the development of new therapies designed to treat multiple diseases of the immune system.
描述(由申请人提供):T细胞受体(TCR)在T淋巴细胞上的参与启动信号通路,通过激活调节基因表达程序的转录因子来调节细胞增殖、激活和存活。当抗原呈递细胞(APC)在适当的分子环境下向T细胞呈递抗原时,TCR信号就会启动。APC与T细胞结合后,在细胞接触区形成免疫突触。从突触到转录因子的信号需要向免疫突触募集信号中间体,这一过程尚不完全清楚。CARD11是一种多结构域适配器蛋白,可协调tcr介导的NF-kappaB激活所需的一组蛋白的信号诱导关联。为了扩大我们对CARD11如何将信号从TCR传递到NF-kappaB的理解,我们开发了一种新的表达克隆策略来鉴定CARD11信号活性的调节剂。使用这种策略,我们分离出了作为CARD11负调节因子的运动蛋白GAKIN。在我们的初步研究中,我们已经确定GAKIN过表达抑制CARD11活性和TCR信号传导,而GAKIN表达减少导致CARD11和TCR信号传导增强。GAKIN和CARD11在T细胞内源性水平上以信号诱导的方式结合。影像学研究表明,在TCR信号传导过程中,GAKIN的细胞定位会发生变化,这可能取决于GAKIN作为一种运动蛋白沿着微管移动货物的能力。在这个应用中,我们建议验证我们的总体假设,即GAKIN是TCR信号的关键负调节因子,调节CARD11的支架功能和细胞定位。使用生化方法,我们将研究GAKIN的哪些结构域与CARD11的关联以及其负调控TCR信号传导的能力是必需的。我们还将确定GAKIN是否调节信号辅助因子与CARD11的关联。在成像实验中,我们将描述GAKIN的定位是如何确定的,以及GAKIN是否调节CARD11和免疫突触信号因子的募集。GAKIN与CARD11在弥漫性大B细胞淋巴瘤(DLBCL)中发现的致癌突变区域相关。我们将研究这些突变是否会影响GAKIN介导的CARD11活性调节,并确定GAKIN是否可以抑制DLBCL中失调的生长。我们的研究结果应该有助于理解免疫细胞的分子机制如何识别和解释环境信号,包括致病性和非致病性刺激,并做出适当的反应。由于这种机制在衰老的T细胞中受损,在免疫缺陷中失调,在自身免疫性疾病和几种类型的癌症中异常亢进,我们的研究结果可能为开发治疗多种免疫系统疾病的新疗法提供分子靶点。公共卫生相关性:免疫系统的正常功能取决于白细胞或淋巴细胞检测外来病原体并作出适当反应的能力,从而在不损害宿主的情况下消除病原体。这一建议旨在扩大对T淋巴细胞在这一过程中使用的分子机制的理解。由于这种机制在衰老的T细胞中受损,在免疫缺陷中失调,在自身免疫性疾病和几种类型的癌症中异常亢进,我们的研究结果可能为开发治疗多种免疫系统疾病的新疗法提供分子靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joel L Pomerantz其他文献

Joel L Pomerantz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joel L Pomerantz', 18)}}的其他基金

Targeting a Membrane Protease that Controls NK Cell Maturation
靶向控制 NK 细胞成熟的膜蛋白酶
  • 批准号:
    10631217
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
Targeting a Membrane Protease that Controls NK Cell Maturation
靶向控制 NK 细胞成熟的膜蛋白酶
  • 批准号:
    10506509
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
  • 批准号:
    10063977
  • 财政年份:
    2019
  • 资助金额:
    $ 40.18万
  • 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
  • 批准号:
    10528445
  • 财政年份:
    2019
  • 资助金额:
    $ 40.18万
  • 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
  • 批准号:
    10304147
  • 财政年份:
    2019
  • 资助金额:
    $ 40.18万
  • 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
  • 批准号:
    8704412
  • 财政年份:
    2013
  • 资助金额:
    $ 40.18万
  • 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
  • 批准号:
    9056446
  • 财政年份:
    2013
  • 资助金额:
    $ 40.18万
  • 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
  • 批准号:
    8829795
  • 财政年份:
    2013
  • 资助金额:
    $ 40.18万
  • 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
  • 批准号:
    8554256
  • 财政年份:
    2013
  • 资助金额:
    $ 40.18万
  • 项目类别:
Motor protein regulation of T cell receptor signaling
T 细胞受体信号传导的运动蛋白调节
  • 批准号:
    7648345
  • 财政年份:
    2009
  • 资助金额:
    $ 40.18万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 40.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
    Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 40.18万
  • 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 40.18万
  • 项目类别:
    Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 40.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 40.18万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    9922602
  • 财政年份:
    2020
  • 资助金额:
    $ 40.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了